ArticlePloS one2026
Mesothelial cells derived extracellular vesicles promote angiogenesis through the transfer of angiopoietin-2.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal mesothelial cells play a critical role in shaping the peritoneal tumor microenvironment and are increasingly recognized as active regulators of angiogenesis in cancers that metastasize to the peritoneum, including gastrointestinal (GI) and ovarian malignancies. Through complex interactions with tumor and stromal cells, peritoneal mesothelial cells contribute to the establishment of a pre-metastatic niche in the peritoneal cavity. Extracellular vesicles (EVs), nanosized vesicles secreted by most cell types, mediate intercellular communication by transferring bioactive molecules such as proteins, lipids, and nucleic acids. While tumor-derived EVs have been extensively studied in cancer progression, the role of mesothelial cells-derived EVs in regulating endothelial function and angiogenesis remains largely unexplored.
methodsEVs were isolated from conditioned media of mesothelial cells and characterized before functional assays. Their effects on endothelial cell behavior were assessed using proliferation, migration, and invasion assays, as well as Matrigel-based tube formation and in vivo angiogenesis plug models. A proteome profiler angiogenesis array was used to identify enriched pro-angiogenic mediators. Mechanistic studies were conducted using lentiviral knockdown and overexpression strategies.
resultsEndothelial cells efficiently internalized mesothelial cells-derived EVs, leading to significant increases in proliferation, migration, invasion, and angiogenesis in vitro and in vivo. Proteomic profiling identified 43 angiogenic regulators within mesothelial cells-derived EVs, with angiopoietin-2 (ANG2) emerging as a key effector. Functional analyses demonstrated that mesothelial cells-derived EVs-induced angiogenesis was mediated through ANG2-TIE2 signaling, with subsequent activation of PI3K, Akt, and ERK1/2 pathways. Importantly, inhibition of ANG2 markedly reduced these angiogenic effects.
conclusionsThis work establishes that EVs secreted by mesothelial cells promote angiogenesis by reprogramming endothelial cells through ANG2-dependent signaling. These findings uncover a novel mechanism of mesothelial-endothelial communication and highlight the ANG2 pathway as a promising therapeutic target in advanced GI cancers with peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.